Sarepta Therapeutic (SRPT) Eteplirsen NDA Filing on Track for Year-End, Needham & Company

August 7, 2014 11:55 AM

Needham & Company analyst Chad Messer, Ph.D reiterated a Buy rating and $52 price target on Sarepta Therapeutic (NASDAQ: SRPT) ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found